1. Home
  2. RCUS vs ARQT Comparison

RCUS vs ARQT Comparison

Compare RCUS & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$23.88

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$29.59

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCUS
ARQT
Founded
2015
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.3B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
RCUS
ARQT
Price
$23.88
$29.59
Analyst Decision
Buy
Strong Buy
Analyst Count
8
7
Target Price
$29.38
$24.83
AVG Volume (30 Days)
2.0M
1.8M
Earning Date
10-28-2025
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$240,000,000.00
$317,929,000.00
Revenue This Year
N/A
$85.51
Revenue Next Year
N/A
$30.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
129.21
52 Week Low
$6.50
$11.13
52 Week High
$26.40
$31.77

Technical Indicators

Market Signals
Indicator
RCUS
ARQT
Relative Strength Index (RSI) 58.38 56.35
Support Level $22.60 $27.71
Resistance Level $23.62 $30.26
Average True Range (ATR) 1.13 1.02
MACD -0.12 -0.24
Stochastic Oscillator 62.61 74.59

Price Performance

Historical Comparison
RCUS
ARQT

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Share on Social Networks: